Characterization of two new monoclonal antibodies against human papillomavirus type 16 L1 protein

详细信息    查看全文

• 作者：Yan Wang (8) (9)
  Qinglong Shang (8) (9)
  Weizhen Xu (8) (9)
  Di Li (8) (9)
  Hongxi Gu (8) (9)
  Lanlan Wei (8) (9)
  
  8. Department of Microbiology ; Heilongjiang Key Laboratory of Infection and Immunity ; Harbin Medical University ; Harbin ; 150081 ; China
  9. Pathogenic-Biological Key Laboratory of Heilongjiang Province ; Harbin Medical University ; Harbin ; 150081 ; China
  
• 关键词：Human papillomavirus ; Monoclonal antibody ; Variable regions
• 刊名：Diagnostic Pathology
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：9
• 期：1
• 全文大小：1,601 KB
• 参考文献：1. De Vuyst, H, Clifford, G, Li, N, Franceschi, S (2009) HPV infection in Europe. Eur J Cancer 45: pp. 2632-2639 CrossRef
  2. Franceschi, S (2005) The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer. Recent Results Cancer Res 166: pp. 277-297 CrossRef
  3. Kreimer, AR, Clifford, GM, Boyle, P, Franceschi, S (2005) Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 14: pp. 467-475 CrossRef
  4. Garc铆a-Espinosa, B, Moro-Rodr铆guez, E, Alvarez-Fern谩ndez, E (2013) Human papillomavirus genotypes in human immunodeficiency virus-positive patients with anal pathology in Madrid. Spain. Diagn Pathol 8: pp. 204 CrossRef
  5. Frazer, IH (2010) Cervical cancer vaccine development. Sex Health 7: pp. 230-234 CrossRef
  6. Luciani, S, Jauregui, B, Kieny, C, Andrus, JK (2009) Human papillomavirus vaccines: new tools for accelerating cervical cancer prevention in developing countries. Immunotherapy 1: pp. 795-807 CrossRef
  7. Carestiato, FN, Silva, KC, Balthazar, DS, Silva, L, Marinho, M, Oliveira, LH, Cavalcanti, SM (2006) Analysis of molecular biology techniques for the diagnosis of human papillomavirus infection and cervical cancer prevention. Rev Soc Bras Med Trop 39: pp. 428-432 CrossRef
  8. Matsukura, T, Sugase, M (2008) Pitfalls in the epidemiologic classification of human papillomavirus types associated with cervical cancer using polymerase chain reaction: driver and passenger. Int J Gynecol Cancer 18: pp. 1042-1050 CrossRef
  9. Fraser, C, Tomassini, JE, Xi, L, Golm, G, Watson, M, Giuliano, AR, Barr, E, Ault, KA (2007) Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine 25: pp. 4324-4333 CrossRef
  10. Ohlschl盲ger, P, Osen, W, Dell, K, Faath, S, Garcea, RL, Jochmus, I, M眉ller, M, Pawlita, M, Sch盲fer, K, Sehr, P, Staib, C, Sutter, G, Gissmann, L (2003) Human papillomavirus type 16聽L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J Virol 77: pp. 4635-4645 CrossRef
  11. Schiller, JT, Lowy, DR (2001) Papillomavirus-like particle based vaccines: cervical cancer and beyond. Expert Opin Biol Ther 1: pp. 571-581 CrossRef
  12. Chen, PP (1990) Structural analyses of human developmentally regulated Vh3 genes. Scand J Immunol 31: pp. 257-267 CrossRef
  13. Wilson, N, Simpson, R, Cooper-Liddell, C (2009) Introductory glycosylation analysis using SDS-PAGE and peptide mass fingerprinting. Methods Mol Biol 534: pp. 205-212
  14. Matoba, N, Kajiura, H, Cherni, I, Doran, JD, Bomsel, M, Fujiyama, K, Mor, TS (2009) Biochemical and immunological characterization of the plant-derived candidate human immunodeficiency virus type 1 mucosal vaccine CTB-MPR. Plant Biotechnol J 7: pp. 129-145 CrossRef
  15. Mageed, RA, Harmer, IJ, Wynn, SL, Moyes, SP, Maziak, BB, Br眉ggemann, M, MacKworth-Young, CG (2001) Rearrangement of the human heavy chain variable region gene V3-23 in transgenic mice generates antibodies reactive with a range of antigens on the basis of VHCDR3 and residues intrinsic to the heavy chain variable region. Clin Exp Immunol 123: pp. 1-8 CrossRef
  
• 刊物主题：Pathology;
• 出版者：BioMed Central
• ISSN：1746-1596

文摘

Background Human papillomavirus type 16 (HPV16) infection is implicated in cervical carcinogenesis. This study aimed to characterize two new monoclonal antibodies (mAbs) against HPV L1 protein. Methods The immunocompetence of AE3 and AG7 mAbs for HPV L1 protein was evaluated by Western blot analysis, immunostaining, hemagglutination inhibition assay, and ELISA. The heavy chain variable region (VH) and light chain variable region (VL) of AE3 and AG7 mAbs were sequenced and analyzed. Results Both mAbs specifically recognized HPV16 L1 and virus-like particles (VLPs). Both the affinity and the titer of AE3 mAb were higher than that of AG7. There were differences in sequences in the complementary determining regions (CDR) 2 and 3 of VL, as well as in the CDR1 and CDR3 of VH. The two mAbs have distinct predicted three-dimensional structures. Conclusions We characterized two mAbs neutralizing antibodies for HPV L1 protein, which would help develop genetic-engineered neutralizing antibodies against HPV16 for diagnostic and therapeutic purposes.